Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corchorusoside C is a cardenolide natural product isolated from the plant *Streptocaulon juventas*. It is being investigated as a potential antineoplastic agent, particularly for the treatment of prostate cancer. Mechanistically, corchorusoside C targets the noncanonical NF-κB pathway by inhibiting the expression of NF-kappa-B-inducing kinase (NIK), IKKα, and NF-κB p65. Preclinical studies in zebrafish and DU-145 prostate cancer cells have shown that it modulates several key proteins involved in DNA repair and apoptosis, including increasing XRCC-1 expression and decreasing p53 and XIAP levels. Additionally, it has been found to decrease caspase-1 activity and IL-18 expression. In comparative toxicity studies, corchorusoside C demonstrated a more favorable safety profile in zebrafish than its analog digoxin and other common anticancer drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corchorusoside C.